SCHEMBL110286

SCHEMBL110286

O=c1ssc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.43
ALDH1A1 P00352 5/20 0.43
CASP3 P42574 5/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 3/20 0.43
DDAH1 O94760 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
G6PD P11413 2/20 0.40
ALOX15 P16050 1/20 0.39
HPGD P15428 2/20 0.38
PMM2 O15305 1/20 0.38
HSP90AA1 P07900 1/20 0.38
PKM P14618 1/20 0.38
ALOX12 P18054 1/20 0.38
MPI P34949 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PHOSPHO1 Q8TCT1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29436003 1.00 GPR3 (0.43) GPR3ALDH1A1CASP3MAPTKDM4E
SCHEMBL13781133 0.83 ALDH1A1 (0.39) GPR3ALDH1A1CASP3MAPTKDM4E
SCHEMBL6067705 0.72 CDK4 (0.44) ALDH1A1CASP3MAPTKDM4EDDAH1
SCHEMBL31458576 0.69
SCHEMBL3107062 0.69
SCHEMBL3075163 0.68 GPR3 (0.43) GPR3ALDH1A1CASP3MAPTKDM4E
SCHEMBL11148877 0.67 GPR3 (0.42) GPR3ALDH1A1CASP3MAPTKDM4E
Lithium SCHEMBL11145683 0.67 GPR3 (0.42) GPR3ALDH1A1CASP3MAPTKDM4E
SCHEMBL9160474 0.65 GPR3 (0.68) GPR3ALDH1A1CASP3MAPTKDM4E
SCHEMBL30515127 0.65 GPR3 (0.68) GPR3ALDH1A1CASP3MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4526944-A1 THTOCARBONATE COMPOSITIONS FOR LITHIUM- SULFUR BATTERIES Conamix Inc. (US) 2025-03-26 EP claimed
EP-3475292-B1 SYNTHESIS OF THIOLATED OLIGONUCLEOTIDES WITHOUT A CAPPING STEP BIOGEN MA INC (US) 2024-09-18 EP claimed
WO-2023225261-A1 THTOCARBONATE COMPOSITIONS FOR LITHIUM- SULFUR BATTERIES CONAMIX INC. (US) 2023-11-23 WO claimed
CN-108473526-B Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide 味之素株式会社 2022-08-09 CN claimed
EP-3950698-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE AJINOMOTO CO., INC. (JP) 2022-02-09 EP claimed
US-20220010348-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE AJINOMOTO CO., INC. (JP) 2022-01-13 US claimed
CN-113631564-A Method for producing oligonucleotide having phosphorothioate moiety 味之素株式会社 2021-11-09 CN claimed
US-10919928-B2 Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide AJINOMOTO CO., INC. (JP) 2021-02-16 US claimed
WO-2020196890-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE 味の素株式会社 2020-10-01 WO claimed
EP-3398955-A1 OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2018-11-07 EP claimed
US-5616700-A GENETIC ENGINEERING BECKMAN INSTRUMENTS, INC. (US) 1997-04-01 US claimed
WO-1996039413-A1 METHODS AND COMPOUNDS FOR THE SYNTHESIS OF OLIGONUCLEOTIDES AND THE OLIGONUCLEOTIDES THEREBY PRODUCED HYBRIDON, INC. (US) 1996-12-12 WO claimed
EP-0746614-A1 METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES RIBOZYME PHARMACEUTICALS, INC. (US) 1996-12-11 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
WO-1996014277-A1 SYNTHESIS OF 35S-LABELED OLIGONUCLEOTIDES WITH 3H-1,2-BENZODITHIOL-3-1,1-DIOXIDE HYBRIDON, INC. (US) 1996-05-17 WO claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
WO-1995023225-A2 METHOD AND REAGENT FOR INHIBITING THE EXPRESSION OF DISEASE RELATED GENES RIBOZYME PHARMACEUTICALS, INC. (US) 1995-08-31 WO claimed
WO-1995014029-A1 PROTECTED OLIGONUCLEOSIDES AND THEIR USE IN HIGH YIELDING SYNTHESIS OF DNA AND ANTISENSE DNA BECKMAN INSTRUMENTS, INC. (US) 1995-05-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220010348-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE RNGTT, NUDT1, ADAR GPR3 3997/4885ALDH1A1 3105/4885CASP3 1240/4885
US-10919928-B2 Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide POLL, POLM, NUDT1 GPR3 3932/4885ALDH1A1 1780/4885CASP3 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.